CD274 and hepatocellular carcinoma: At present, the combination of the anti-PDL1 antibody Atezolizumab and the vascular endothelial growth factor (VEGF) neutralizing antibody Bevacizumab has become the first-line treatment for patients with advanced HCC [3].